CLRN2

Across TCGA pan-cancer cohorts, CLRN2 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated CLRN2 data layer compared with 2 for mutation status.

The strongest signal is observed in thyroid carcinoma (THCA), where higher CLRN2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CLRN2 expression acts as an unfavorable survival marker, although some lineages such as PAAD and GBM show a favorable association.

THCA, UVM, and ESCA are the cancer types where CLRN2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Tertile	II,III,IV	0.820	0.981	<.001	72	view →
UVM	OS	Tertile	All	0.317	0.938	<.001	45	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
PAAD	DFS	Tertile	All	0.680	0.246	.004	30	view →
ACC	OS	Median	III,IV	0.588	0.850	.005	25	view →
DLBC	DFS	Median	III,IV	0.140	0.917	.010	23	view →
THYM	DFS	Tertile	III,IV	0.214	1.000	.008	18	view →
MESO	DFS	Tertile	IV	0.130	0.405	.019	18	view →
SKCM	DFS	Tertile	IV	0.036	0.433	<.001	9	view →
GBM	OS	Tertile	All	0.336	0.232	.042	4	view →
PCPG	OS	Tertile	All	0.821	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CLRN2–THCA (OS)

Open the THCA breakdown →